Targeted Albumin Therapy Does Not Improve Short-Term Outcome in Hyponatremic Patients Hospitalized With Complications of Cirrhosis: Data From the ATTIRE Trial

Am J Gastroenterol. 2021 Nov 1;116(11):2292-2295 doi: 10.14309/ajg.0000000000001488.
Abstract
INTRODUCTION:

Patients with decompensated cirrhosis and hyponatremia have a poor prognosis. We investigated Albumin to Prevent Infection in Chronic Liver Failure trial data to determine whether targeted albumin infusions improved outcome in patients with hyponatremia at baseline.

METHODS:

We examined the interaction between targeted albumin and standard care for the composite primary end point, stratifying by baseline sodium ≥ and <130 mmol/L.

RESULTS:

Randomization to albumin was associated with a significant increase in sodium; however, there was no interaction between sodium category and treatment for the trial primary end point.

DISCUSSION:

Targeted intravenous albumin infusions increased serum sodium level in hospitalized hyponatremic patients with cirrhosis, but this did not improve outcome.

Metadata
MESH HEADINGS: Albumins; Hospitalization; Humans; Hyponatremia; Infusions, Intravenous; Liver Cirrhosis; Time Factors; Treatment Outcome
Study Details
Study Design: Randomised Controlled Trial
Language: eng
Credits: Bibliographic data from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine